What's new: Natural and non-prescription health products 

• Lifting the interim policy for cleaning products for use, handling or storage in workplaces (COVID-19): Notice [2022-04-12]
• Lifting the interim policy for household cleaning products, hand soaps and body soaps (COVID-19): Notice [2022-04-12]
• Notice: Clinical trials for medical devices and drugs relating to COVID-19 regulations [2022-03-02]
• Notice of updated guidance: Applications for COVID-19 drug clinical trials under the Regulations [2022-03-02]
• Notice: Period reduced for keeping clinical trial records for drugs and natural health products [2022-03-02]
• What we heard report: Records retention consultations related to the clinical trials interim order transition regulations [2021-11-19]
• Production of isopropyl alcohol for use in alcohol-based hand sanitizers: interim guide
• Applying for a Drug Identification Number (DIN) for a disinfectant drug during the COVID-19 pandemic
• Alcohol-based hand sanitizers in beverage and food containers: Packaging and labelling requirements to reduce unintentional ingestion risk
• Applying for a Drug Identification Number (DIN) to distribute or sell hand sanitizer
• Manufacturers of hand sanitizers using technical-grade ethanol
• Labelling of hand sanitizers, disinfectants, soaps and cleaning products in the context of the COVID-19 response
• Technical-grade ethanol for the manufacture of hand sanitizers during the COVID-19 pandemic: Risk assessment summary report
• Suppliers of technical grade ethanol for use in the production of hand sanitizers
• Health Product Advertising Incidents related to COVID-19
• Health Canada's decision to temporarily allow technical grade ethanol for the manufacture of hand sanitizers - Notice to industry
• COVID-19 health product industry
• Hard surface disinfectants and hand sanitizers (COVID-19)
• Interim guide on the production of ethanol for use in alcohol-based hand sanitizers
• Guide on Health Canada's Interim Expedited Licensing Approach for the Production and Distribution of Alcohol-Based Hand Sanitizers

August

• Notice: Multiple additions to the Prescription Drug List (PDL) [2026-08-27]
• Information about the Prescription Drug List: Notice [2026-08-26]

July

• How  to apply for market authorization for a non-prescription drug [2026-07-31]
• New guidance and public search portal for clinical trials approved in Canada: Notice [2026-07-29]
• Consultation: Draft revised Quality of natural health products guide [2026-07-20]

June

• Notice: Multiple additions to the Prescription Drug List (PDL) [2026-06-25]
• Health Canada has changed the Prescription Drug List qualifier related to pediatric melatonin use: Notice of amendment [2026-06-02]

May

• Updated: Guidance on nitrosamine impurities in medications [2026-05-29]
• Health Canada is changing the Prescription Drug List qualifier related to pediatric melatonin use: Notice of intent [2026-05-26]
• Notice of intent to publish a Ministerial Order to exempt certain low-risk non-prescription drugs from Division 8 provisions in the Food and Drugs Regulations [2026-05-15]
• Notice of consultation: Proposed change to the veterinary omeprazole listing on the Prescription Drug List [2026-05-13]
• Consultation: Updates to the NHP Compounding and Raw Material Policies [2026-05-13]

April

• Notice: Multiple additions to the Prescription Drug List (PDL) [2026-04-30]
• Public Notice: Classification of sports electrolyte products as foods [2026-04-23]
• ICH guidelines implemented by Health Canada [2026-04-01]

March

• Regulatory Overview: Non-prescription drugs in Canada
• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2026-03-11]

February

• Notice: Multiple additions to the Prescription Drug List (PDL) [2026-02-26]
• Towards a pathway for health products containing cannabidiol: What we heard report [2026-02-16]
• Notice of consultation: Removing zuranolone from the Prescription Drug List (PDL) [2026-02-09]

January

• Notice of amendment: Revisions to the Prescription Drug List for nicotine buccal pouches [2026-01-14]
• Consultation: Release of draft ICH E22 - General considerations for patient preference studies [2026-01-12]
• ICH guidelines implemented by Health Canada [2026-01-12]

December

• Notice: Multiple additions to the Prescription Drug List (PDL) [2025-12-18]
• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2025-12-17]

November

• Updated: Guidance document - Preparation of regulatory activities in non-eCTD format [2025-11-27]
• Updated: Filing submissions electronically [2025-11-05]

October

• Notice: Multiple additions to the Prescription Drug List (PDL) [2025-10-30]
• Implementation of International Council for Harmonisation (ICH) Q12 - Technical and regulatory considerations for pharmaceutical product lifecycle management: Notice [2025-10-17]
• Release of draft (step 2) ICH Guideline Q3E: Impurities: Guideline for extractables and leachables [2025-10-17]

September

• Consultation: Adding melatonin for sleep-related use in the pediatric population to the Prescription Drug List [2025-09-16]
• Third party authorization form [2025-09-10]
• Notice of amendment: Addition of melatonin to the Prescription Drug List [2025-09-09]
• Health Canada and the Public Health Agency of Canada’s report on red tape reduction [2025-09-08]
• Good manufacturing practices guide for natural health products (GUI-0158) [2025-09-04]

August

• Notice: Multiple additions to the Prescription Drug List (PDL) [2025-08-28]
• Notice to stakeholders: Publication of Non-prescription Drug Cough, Cold and Flu Labelling Standard [2025-08-19]
• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2025-08-01]
• Updated: Guidance on nitrosamine impurities in medications [2025-08-01]

July

• Notice of amendment: Nicotine tablets exempted from the Prescription Drug List [2025-07-21]
• Notice of intent: Revisions to the Prescription Drug List for nicotine buccal pouches [2025-07-14]
• Notice of intent: Exempting nicotine tablets from the Prescription Drug List [2025-07-14]
• Notice: Revisions to the Drug Product Database's terminology page [2025-07-04]

June

• Notice to stakeholders – Implementation of ICH M13A: Bioequivalence for immediate release solid oral dosage forms [2025-06-27]
• Q13: Continuous manufacturing of drug substances and drug products [2025-06-27]
• Q5A(R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin [2025-06-27]
• Q3C(R9): Impurities: Residual solvents [2025-06-27]
• Release of draft (step 2) ICH guideline Q1: Stability testing of drug substances and drug products [2025-06-27]
• Release of draft (Step 2) ICH guideline M13B: Bioequivalence for immediate-release solid oral dosage forms [2025-06-27]
• Release of draft (Step 2) ICH guideline M4Q(R2): Common Technical Document (CTD)-Quality [2025-06-27]
• Release of draft (Step 2) ICH guideline E20: Adaptive clinical trials [2025-06-27]
• Release of draft (Step 2) ICH guideline E21: Inclusion of pregnant and breastfeeding individuals in clinical trials [2025-06-27]
• Release of draft (Step 2) ICH M11: Clinical electronic Structured Harmonised Protocol (CeSHarP) – Technical specification [2025-06-27]
• Notice: Multiple additions to the Prescription Drug List (PDL) [2025-06-24]

April

• Notice: Multiple additions to the Prescription Drug List (PDL) [2025-04-29]
• Updated: Filing submissions electronically [2025-04-25]

March

• Nitrosamine impurities in medications: Recalls [2025-03-31]
• Guidance Document: Preparation of the XML Product Monograph (XML PM) [2025-03-28]
• Publication: Exemption Order in Respect of Labelling Requirements for Certain Natural Health Products [2025-03-26]
• Guide to the precision regulating authorities under the Food and Drugs Act [2025-03-14]
• Consultation: Towards a Pathway for Health Products Containing Cannabidiol [2025-03-07]
• Workload Management for Class III Natural Health Product Submissions [2025-03-05]

February

• Notice: Multiple Additions to the Prescription Drug List (PDL) [2025-02-26]
• Notice of intent to publish a targeted Ministerial Order to exempt Natural Health Products from certain labelling provisions in the Natural Health Products Regulations [2025-02-25]
• Updated: Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINs) [2025-02-18]
• Updated: Drug Product Database [2025-02-18]
• Notice of Consultation on the Prescription Drug List (PDL): Nicotine Buccal Pouches [2025-02-13]
• Notice of Consultation on the Prescription Drug List (PDL): Nicotine Tablets [2025-02-13]
• Guide to the Supplementary Rules Respecting Nicotine Replacement Therapies Order [2025-02-12]

January

• Updated: Filing submissions electronically [2025-01-27]
• Notice – Implementation of International Council for Harmonisation (ICH) S1B(R1): Testing for Carcinogenicity of Pharmaceuticals [2025-01-17]

December

• New terms and conditions for human and veterinary drugs: Notice [2024-12-20]
• Notice: Multiple additions to the Prescription Drug List (PDL) [2024-12-20]
• Consultation: Release of Draft (Step 2) ICH guideline, ICH M15 and E6(R3) Annex 2 [2024-12-20]
• Implementation: Release of Final (Step 4) ICH guideline, ICH M12 [2024-12-20]
• Notice of intent to the transition for certain labelling provisions of the Supplementary Rules Respecting Nicotine Replacement Therapies Order: SOR/2024-169 [2024-12-12]
• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2024-12-11]

October

• Guidance on advertising nicotine replacement therapies [2024-10-31]
• Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]
• Natural health products good manufacturing practices pre-inspection package [2024-10-07]
• Notice of Amendment: Iron derivatives for human use on the Prescription Drug List (PDL) [2024-10-04]

September

• How to develop a corrective and preventive action plan (CAPA) [2024-09-27]
• Authorization for a third party to file a regulatory activity on behalf of the manufacturer/sponsor (PDF format) [2024-09-11]

August

• Notice - Release of the final guidance document: "Switching from prescription to non-prescription status" [2024-08-14]

July

• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2024-07-26]
• Consultation: Release of Draft (Step 2) ICH guideline, ICH M14 [2024-07-24]

June

• Nitrosamine impurities in medications: Recalls [2024-06-19]
• Guidance on biocides [2024-06-19]

May

• Updated: Guidance on nitrosamine impurities in medications [2024-05-31]
• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2024-05-31]
• Consultation: Release of Draft (Step 2) ICH guideline, ICH E2D(R1) [2024-05-24]
• Interim Order Concerning the Sale of Certain Natural Health Products Containing Ephedrine or Pseudoephedrine [2024-05-17]
• Explanatory note on the Interim Order Concerning the Sale of Certain Natural Health Products Containing Ephedrine or Pseudoephedrine [2024-05-17]

April

• Notice: Multiple additions to the Prescription Drug List (PDL) [2024-04-30]

March

• Appendix 1: Established acceptable intake (AI) limits for N-nitrosamine impurities [2024-03-28]
• Revisions to proposed fees for natural health products [2024-03-27]
• Notice of Intent to address risks of youth appeal and access to nicotine replacement therapies [2024-03-20]
• Updated: Guidance on nitrosamine impurities in medications [2024-03-15]

February

• Notice: Release of notice for (Step 4) ICH E19: A Selective Approach to Safety Data Collection in Specific Late Stage Pre-approval or Post-approval Clinical Trials [2024-02-27]
• Notice: Posting information in the Drug Product Database online [2024-02-02]

December

• Notice – Implementation of ICH E19: A selective approach to safety data collection in specific late-stage pre-approval or post-approval clinical trials [2023-12-21]
• Notice: Release of revised notice for (Step 4) ICH S1B(R1): Testing for Carcinogenicity of Pharmaceuticals [2023-12-01]

October

• Updated: Natural health product regulation in Canada [2023-10-25]
• Updated: Guidance on nitrosamine impurities in medications[2023-10-20]

September

• Notice: Release of (Step 4) ICH M7(R2) Guideline, Addendum, Q&As - Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [2023-09-29]

August

• Notice: Multiple additions to the Prescription Drug List (PDL) [2023-08-30]

July

• Updated: Guidance on nitrosamine impurities in medications [2023-07-28]
• Notice: Release of (Step 4) ICH S12 Guideline - Nonclinical Biodistribution Considerations for Gene Therapy Products [2023-07-21]

June

• Consultation: Release of Draft (Step 2) ICH guideline, ICH E6(R3) [2023-06-21]
• S1B(R1): Health Canada Notice [2023-06-20]
• S1B(R1): Guideline - Testing for Carcinogenicity of Pharmaceuticals [2023-06-20]

April

• Nitrosamine impurities in medications: Guidance [2023-04-17]

February

• Consultation: Release of Draft (Step 2) ICH guideline, ICH M13 [2023-02-24]

January

• Notice: Release of (Step 4) ICH M10 Guideline and Q&A Document - Bioanalytical Method Validation and Study Sample Analysis [2023-01-20]
• Notice: Joint Health Canada, Canada and FDA, United States Public Consultation on ICH [2023-01-17]

December

• Non-prescription Drug Action Plan [2022-12-08]

November

• Consultation: Release of Draft (Step 2) ICH M11 guideline, technical specification and template [2022-11-18]
• Changes to list of certain non-prescription drugs for distribution as samples (List D): Notice of modification [2022-11-16]
• Consultation: Release of Draft (Step 2) ICH guideline, ICH Q5A(R2) [2022-11-02]

October

• Notice: Multiple additions to the Prescription Drug List (PDL) [2022-10-14]

September

• Consultation Extension: Draft (Step 2) ICH Guideline E11A [2022-09-29]
• Updated: Guidance on nitrosamine impurities in medications [2022-09-01]

August

• Notice: Implementation of (Step 4) ICH Q3D(R2) Guideline - Revision of Q3D(R1) for cutaneous and transdermal products [2022-08-29]
• Health Canada recommendations for implementation of the Revised ICH Harmonised Guideline for Elemental Impurities Q3D(R2) for cutaneous and transdermal products [2022-08-29]
• Notice: Revisions to the performance standards for Post-authorization Division 1 Changes [2022-08-02]
• Updated: Guidance Document Post-Drug Identification Number (DIN) Changes [2022-08-02]

July

• Consultation: Release of Draft (Step 2) ICH guideline, ICH M12 [2022-07-29]
• Consultation: Exceptions to the Prescription Drug List [2022-07-29]
• PDD/BRDD/NNHPD Drug Submission Performance Annual Report – Fiscal Year 2021-2022 [2022-07-25]
• Surface disinfectants for emerging viral pathogens [2022-07-25]
• Amendments to the Natural Health Products Regulations [2022-07-06]
• Labelling of Natural Health Products guidance document [2022-07-06]
• Evidence for Homeopathic Medicines guidance document [2022-07-06]

June

• PDD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q4-2021-2022 [2022-06-30]
• Draft ICH guideline Q2(R2): Revision to Analytical Validation [2021-06-13]
• Draft ICH guideline Q14: Analytical Procedure Development [2021-06-13]
• Draft ICH guideline E11A: Paediatric Extrapolation [2021-06-13]
• Notice: Release of Final (Step 4) ICH Q&A Document, ICH E14/S7B: Questions & Answers - Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential [2022-06-10]

May

• Consultation on proposed Biocides Regulations [2022-05-07]

April

• Comment on the draft revised Guidance document: Switching a medicinal ingredient from prescription to non-prescription status [2022-04-21]

March

• Classification of products for moxibustion: Notice to stakeholders [2022-03-14]
• TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q3-2021-2022 [2022-03-11]
• Notice: Regulations amending certain regulations concerning drugs and medical devices (shortages) [2022-03-02]

February

• What we heard report on the clinical trials regulatory modernization initiative [2022-02-23]

January

• Guidance Document: Special Access Program for Drugs: Guidance Document for Industry and Practitioners [2022-01-05]

December

• TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q2-2021-2022 [2021-12-23]

September

• TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q1-2021-2022 [2021-09-29]

July

• TPD/BRDD/NNHPD Annual Drug Submission Performance report - Fiscal Year 2020-2021 [2021-07-20]
• TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q4-2020-2021 [2021-07-13]

June

• Consultation: Proposed regulations amending the Natural Health Products Regulations - Improving labelling for natural health products [2021-06-25]

April

• Health Canada responds to the Spring 2021 Report of the Commissioner of the Environment and Sustainable Development
• Report of the Commissioner of the Environment and Sustainable Development - Natural Health Products

March

• TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q3-2020-2021 [2021-03-16]

January

• Regulatory innovation for health products [2021-01-29]

December

• Adverse reactions, medical device incidents and health product recalls in Canada: 2019 summary report [2020-12-11]

November

• TPD/BRDD/NNHPD Drug Submission Quarterly Report for January - September 2020 [2020-11-30]

July

• TPD/BRDD/NNHPD Annual Drug Submission Performance report - Fiscal Year 2019-2020 [2020-07-28]

June

• Natural Health Product Licence Application Form version 4.0 [2020-06-15]

April

• Guidance Document on the Distribution of Drugs as Samples [2020-04-29]
• List incorporated by reference

March

• TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q3-2019-2020

December

• TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q2-2019-2020 [2019-12-20]

September

• TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q1-2019-2020 [2019-09-04]

June

• TPD/BGTD/NNHPD Quarterly Drug Submission Performance report for January - March 2019 & TPD/BGTD/NNHPD Annual Drug Submission Performance report for FY2018-2019 [2019-05-31]

March

• Stop illegal marketing of drugs and devices

February

• NNHPD Quarterly Drug Submission Performance report for October - December 2018 [2019-02-25]

November

• NNHPD Quarterly Drug Submission Performance report for July - September 2018 [2018-11-26]
• Web-based Natural Health Product Licence Application Form (web PLA form) [2018-11-26]

August

• NHPD Quarterly Drug Submission Performance report for April - June 2018 [2018-08-24] [2018-08-24]

July

• Sunscreen
• Poster: Sunscreen tips

June

• TPD Quarterly Drug Submission Performance report for Q4-2017-2018, BGTD Quarterly Drug Submission Performance report for Q4-2017-2018, NNHPD Quarterly Drug Submission Performance report for Q4-2017-2018 [2018-06-15]

March

• NNHPD Quarterly Drug Submission Performance report for Q3-2017-2018 [2018-03-02]

January

• Notice - Updates to the Prescription Drug List [2018-01-04]
• Updates to the Prescription Drug List [2018-01-04]

November

• TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q2-2017-2018 [2017-11-29]

October

• Notice - Prescription Drug List (PDL): Multiple Additions [2017-10-19]
• Updates to the Prescription Drug List [2017-10-19]

September

• Natural and Non-prescription Health Products Directorate Upcoming activities: Aug to Dec 2017 [2017-09-01]

August

• Therapeutic Products Directorate (TPD), Biologics and Genetic Therapies Directorate (BGTD), Natural and Non-Prescription Health Products Directorate (NNHPD) Drug Submission Performance Quarterly Reports - April - June 2017 [2017-08-29]

June

• Updates to the Prescription Drug List [2017-06-23]

May

• Natural and Non-prescription Health Products Directorate (NNHPD) Upcoming activities: May 1, 2017 to September 30, 2017 [2017-07-14]
• Updates to the Prescription Drug List [2017-05-19]

April

• Updates to the Prescription Drug List [2017-04-21]

March

• Updates to the Prescription Drug List [2017-03-29]

February

• Updates to the Prescription Drug List [2017-02-10]

November

• Updates to the Prescription Drug List [2016-11-16]

September

• Guidance Document: Acetaminophen Labelling Standard [2016-09-15]
• Consultation - Regulation of self-care products [2016-09-08]

August

• Prescription Drug List [2016-08-26]
• Prescription Drug List [2016-08-18]
• Prescription Drug List [2016-08-09]

May

• Update - Natural Health Products Online Solution: Frequently Asked Questions [2016-05-16]
• Update - Notice to Stakeholders Regarding the Results of the Class Redistribution Pilot [2016-05-16]

April

• Updated - Prescription Drug List [2016-04-22]
• The Non-Prescription and Natural Health Products Directorate is moving - new physical and mailing addresses [2016-04-14]

March

• Updated - Prescription Drug List [2016-03-22]

February

• Final Mongraph for Antiseptic Skin Cleanser [2016-02-09]
• Consultation - Revised Monograph (Multi-Vitamin/Mineral Supplements) [2016-02-09]

January

• Communication on changes to the Non-prescription Drug Monograph Attestation Process [2016-01-15]
• Revised Monograph (White Kidney Bean Extract) [2016-01-12]
• Consultation - Revised Monograph (Acne Therapy) [2016-01-26]
• Prescription Drug List [2016-01-08]

December

• Final Monograph for Hydrocortisone [2015-12-08]
• Final Monograph for Maitake [2015-12-08]
• Final Monograph for Poria [2015-12-08]
• Final Monograph for Mushrooms [2015-12-08]
• Final Monograph for Pygeum [2015-12-08]
• Final Monograph for Aromatherapy [2015-12-08]
• Final Monograph for Indole-3-carbinol [2015-12-08]
• Final Monograph for 3,3'-Diindolylmethane (DIM) [2015-12-08]
• Final Monograph for Soy Flour [2015-12-08]
• Final Monograph for Betaine/Betaine Hydrochloride [2015-12-08]
• Final Monograph for Bearberry [2015-12-08]
• Final Monograph for Olive Leaf [2015-12-08]
• Good Manufacturing Practices Guidance Document [2015-12-01]
• Site Licensing Guidance Document [2015-12-01]
• Notice to Stakeholders Regarding Site Licensing Update [2015-12-01]

October

• Notice - Prescription Drug List (PDL): Multiple Additions [2015-10-16]

August

• Prescription Drug List [2015-08-12]

July

• Information on Homeopathic Products [2015-07-31]
• Revised Guidance Document (Homeopathic Medicines) [2015-07-31]
• Finalized Revised Labelling Standard (Topical Anaesthetic, Analgesic, Antipruritic) [2015-07-29]
• Finalized New Labelling Standard (Oral Adult Antitussive) [2015-07-28]
• Finalized New Labelling Standard (Oral Stool Softener Laxatives) [2015-07-28]
• Revised Monograph (American ginseng) [2015-07-08]

June

• Prescription Drug List [2015-06-26]
• Revised Monograph (Hard Surface Disinfectants)
• Revised Monograph (Traditional Chinese Medicine Ingredients)
• Revised Monograph (Homeopathy)

May

• Prescription Drug List [2015-05-29]
• Quality of Natural Health Products Guide [2015-05-12]

April

• Non-prescription Oral Adult Antitussive Cough and Cold Labelling Standard [2015-04-01]
• Revised Labelling Standard (Oral Stool Softener Laxatives) [2015-04-01]

March

• Prescription Drug List [2015-03-26]

February

• Natural and Non-prescription Health Products Directorate (NNHPD) six-month calendar of activities: January to June 2015 [2015-02-27]

January

• Consultation - New and Revised Monographs (Mushrooms, Poria - Wolfiporia extensa and Maitake - Grifola frondosa) [2015-01-20]
• Prescription Drug List [2015-01-14]
• Consultation - Revised Monograph (Hard Surface Disinfectants Monograph) [2015-01-07]

December

• Consultation - Revised Monograph (Hydrocortisone - Topical) [2014-12-29]
• Prescription Drug List [2014-12-24]
• Consultation - Revised Labelling Standard (Topical Anaesthetic, Analgesic, Antipruritic) [2014-12-19]
• Prescription Drug List [2014-12-05]

November

• Consultation - Development of new monograph (Chlorella) [2014-11-18]
• Consultation - Development of new monographs (Betaine/Betaine Hydrochloride and Olive Leaf - Olea Europaea) [2014-11-04]
• Management of product licence applications for natural health products [2014-11-03]

October

• Consultation -Development of new monographs (Bearberry - Arctostaphylos uva-ursi and Aromatherapy - Essential Oils) [2014-10-07]

September

• Prescription Drug List [2014-09-16]

August

• Consultation - Development of new and revised monographs (Aloe Vera Leaf Gel - oral, African Wild Mango, Kutki and Antiseptic Skin Cleansers) [2014-08-26]
• Prescription Drug List [2014-08-22]

July

• Non-prescription drug monograph attestation pilot [2014-07-10]
• Prescription Drug List [2014-07-02]

June

• Management of product licence applications for natural health products [2014-06-30]
• Consultation - Development of new monograph (Cognitive Function Products and Royal Jelly) [2014-06-17]
• Consultation - Site licensing guidance document [2014-06-13]
• Consultation - Quality Assurance Report form [2014-06-13]
• Consultation - Good Manufacturing Practices Guidance Document [2014-06-13]

May

• Expectorant - Adult [2014-05-30]
• Topical Nasal Decongestants [2014-05-30]
• Consultation - Development of new monograph (Red Clover Isoflavone Extract) [2014-05-21]
• Prescription Drug List [2014-05-12]
• Data requirements for switching medicinal ingredients from prescription to non-prescription status [2014-05-07]

April

• Consultation - Development of new Monograph (Black Walnut) [2014-04-23]
• Consultation - Development of new and revised monographs (Spirulina, Oral Health Products and Reishi) [2014-04-08]

March

• Consultation - Development of new monographs (Ubiquinol, Serrapeptase, and Triphala) [2014-03-11]

February

• Prescription Drug List [2014-02-18]
• Consultation - Message to natural health product stakeholders regarding the development of a monograph: Traditional Chinese Medicine Ingredients [2014-02-11]

January

• Common Electronic Submissions Gateway [2014-01-31]
• Consultation - Message to natural health product stakeholders regarding development of pre-cleared information [2014-01-28]
• Consultation - A Revised Approach to NHP Site Licensing [2014-01-23]
• Updated - Natural health products online system standard terminology guide [2014-01-10]
• Natural Health Product Licence Application Form User Manual [2014-01-10]
• Guidance document on how to interact with the Natural Health Products Directorate electronically [2014-01-06]